



4-15-08

JFW 1635
PTO/SB/21 (2-1-07)

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

 TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/551,667
		Filing Date	July 18, 2006
		First Named Inventor	Patrick Y. Lu
		Art Unit	1635
		Examiner Name	Tracy Ann Vivlemore
Total Number of Pages in This Submission		Attorney Docket Number	INTM/017

ENCLOSURES *(Check all that apply)*

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> <input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1) Form PTO/SB/08a;
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	2) 19 Cited References; and
	<input type="checkbox"/> Landscape Table on CD	3) Return Receipt Postcard
<p>Remarks</p> <p>The Director is hereby authorized to charge payment of any fees required in connection with filing of these papers to Deposit Account No. 06-1075, Order No. 104825-0017. A duplicate copy of this letter is transmitted herewith.</p>		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Ropes & Gray LLP		
Signature			
Printed name	Alla Brukman		
Date	April 16, 2008	Reg. No.	61,254

CERTIFICATE OF EXPRESS MAIL (EXPRESS MAIL LABEL NO. EM014768875US)

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature	
Typed or printed name	SARAH SCHLIE
Date	April 16, 2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.FormsWorkflow.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Patrick Y. Lu et al.
Application No. : 10/551,667 Confirmation No. : 5623
Filed : July 18, 2006
For : TARGETS FOR TUMOR GROWTH INHIBITION
Group Art Unit : 1635
Examiner : Tracy Ann Vivlemore

New York, New York
April 16, 2008

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.R.F. § 1.56 and 1.97, applicants hereby make of record the following documents. Copies of all non-U.S. patent documents are submitted herewith.¹

¹ A completed PTO/SB/08A listing these documents is attached hereto.

United States Patents

<u>Patent No.</u>	<u>Applicant</u>	<u>Issue Date</u>
5,801,154	Baracchini et al.	09-01-1998
6,506,559	Fire et al.	01-14-2003

Foreign Patent Publications

<u>Publication No.</u>	<u>Publication Date</u>
WO 95/15171	06-08-1995
WO 00/30667	06-02-2000
WO 00/06723	02-10-2000
WO 03/00928	01-03-2003
WO 03/70771	08-28-2003

Non-Patent Literature Documents

CAI et al., "Induction of glucose regulated proteins during growth of a murine tumor," *J. Cell Physiol.*, 154:229-237 (1993).

CARMON et al., "Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/Db-beta2m transgenic mice," *Journal of Clinical Investigation*, 110:453-462 (2002).

COUTO et al., "Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor-like domain," *DNA and Cell Biology*, 15:281-286 (1996).

GORZA et al., "Reduced amount of the glucose-regulated protein GRP94 in skeletal myoblasts results in loss of fusion competence," *The FASEB Journal*, 14:461-475 (2000).

GenBank Accession No. AAA02490.

GenBank Accession No. AAH14425.

GenBank Accession No. AK026010.

GenBank Accession No. AK056708.

GenBank Accession No. BAB15318.

GenBank Accession No. BC014425.

GenBank Accession No. M99624.

GenBank Accession No. NM_022450.

GenBank Accession No. Z69719.

TAYLOR et al., "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," *Drug Discovery Today*, 4:562-567 (1999).

REMARKS

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is submitted before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of the fee to Deposit Account No. 06-1075, Order No. 104825-0017. A duplicate copy of this Statement is enclosed.

Respectfully submitted,


Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants

Alla Brukman (Reg. No. 61,254)
Agent for Applicants

ROPES & GRAY LLP
Customer No. 1473
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax: (212) 596-9090